logo-loader
RNS
viewGlaxoSmithKline PLC

GlaxoSmithKline PLC - Director/PDMR Shareholding

RNS Number : 6484D
GlaxoSmithKline PLC
20 February 2020
 

GlaxoSmithKline plc (the 'Company')

 Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.00

37,221 (Deferred)

 

 

£0.00

24,815 (Matching)

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

62,036

£0.00

e)

Date of the transaction

2020-02-17

f)

Place of the transaction

 

N/A

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£16.614

17,523 (Deferred)

 

 

£16.614

11,680 (Matching)

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

29,203

£16.614

e)

Date of the transaction

2020-02-17

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Connor

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.00

19,375 (Deferred)

 

 

£0.00

12,917 (Matching)

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

32,292

£0.00                                                                              

e)

Date of the transaction

2020-02-17

f)

Place of the transaction

 

N/A

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Connor

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£16.714

9,120 (Deferred)

 

 

£16.714

6,081 (Matching)

 

 

 

 

 

d)

Aggregated information

 

 

 

Aggregated volume Price

 

15,201

£16.714                                                                             

e)

Date of the transaction

2020-02-17

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.00

12,243 (Deferred)

 

 

£0.00

8,163 (Matching)

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

20,406

£0.00                                                                         

e)

Date of the transaction

2020-02-17

f)

Place of the transaction

 

N/A

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£16.678

5,770 (Deferred)

 

 

£16.678

3,846 (Matching)

 

 

 

 

 

d)

Aggregated information

 

 

 

Aggregated volume Price

 

9,616

£16.678                                                                

e)

Date of the transaction

2020-02-17

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053

b)

Nature of the transaction

The sale of ADSs to meet tax liabilities on the vesting of awards under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

$43.544

3,467 (Deferred)

 

 

$43.544

2,423 (Matching)

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

5,890

$43.544                                                                                      

e)

Date of the transaction

2020-02-18

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.00

15,407 (Deferred)

 

 

£0.00

10,273 (Matching)

 

 

 

 

 

d)

Aggregated information

 

 

 

Aggregated volume Price

 

25,680

£0.00                                          

e)

Date of the transaction

2020-02-17

f)

Place of the transaction

 

N/A

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£16.629

7,261 (Deferred)

 

 

£16.629

4,840 (Matching)

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

12,101

£16.629                                         

e)

Date of the transaction

2020-02-17

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.00

7,302 (Deferred)

 

 

£0.00

4,869 (Matching)

 

 

 

 

 

d)

Aggregated information

 

 

 

Aggregated volume Price

 

12,171

£0.00                                                                                  

e)

Date of the transaction

2020-02-17

f)

Place of the transaction

 

N/A

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£16.623

3,442 (Deferred)

 

 

£16.623

2,294 (Matching)

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

5,736

£16.623                                                                           

e)

Date of the transaction

2020-02-17

f)

Place of the transaction

 

London Stock Exchange (XLON)

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHXBLFLBLLEBBQ

Quick facts: GlaxoSmithKline PLC

Price: 1649.8

Market: LSE
Market Cap: £82.83 billion
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE